BackBiolase Overview

Biolase Long Term Debt

Latest long-term debt for BIOL: $210K.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$211000.00
↓ 98.28% YoYΔ $-12.09M vs prior year quarter

Peer trimmed avg / median

Loading

Biolase Long Term Debt History

Loading

Biolase vs. peers: Long Term Debt Comparison

Loading

Biolase Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Biolase (BIOL) FAQ

As of the most recent data (September 2024), BIOL shows a long-term debt of $210K. That compares with $12M in the prior-year period — down 98.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BIOL's long-term debt is now $210K (was $12M) — a 98.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Biolase is outperforming or lagging.

Tracking BIOL's long-term debt over time shows whether Biolase is scaling, shrinking, or reshaping that part of the business. The current reading is $210K That compares with $12M in the prior-year period — down 98.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Biolase's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $210K) with ownership activity and broader fundamentals.

Biolase's long-term debt is $210K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.